NCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
Clinical Trials
8 trialsNCT06647680 2026-03-06
Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）
The Affiliated Hospital of Qingdao University
Phase 2 Recruiting
NCT06811844 2025-07-01
Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC
The First Affiliated Hospital of Xiamen University
Phase 2 Recruiting
NCT06927180 2025-06-23
SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
Henan Cancer Hospital
Phase 2 Recruiting
NCT05918328 2025-03-07
Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC
Henan Cancer Hospital
Phase 2 Recruiting
NCT06276868 2024-12-17
Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer
Henan Cancer Hospital
Phase 2 Recruiting
NCT05659056 2024-04-16
Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT05763992 2023-05-18
BREAKFAST-2
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Recruiting